Challenges in the Codevelopment of Companion Diagnostics
Authors:
- 30 July 2012
- journal article
- review article
- Published by Taylor & Francis in Personalized Medicine
- Vol. 9 (5) , 485-496
Abstract
Therapeutics harnessing the power of personalized medicine have the potential to revolutionize healthcare. Companion diagnostics are critical to this goal and are increasingly relied upon to ensure the effective, safe development and use of a personalized therapeutic. Companion diagnostics are the focus of several recent regulatory guidance documents; the drug-diagnostic codevelopment process has become increasingly relevant and necessary. Despite this, the promise of companion diagnostics has not been fully realized and there are multiple difficulties that still need resolution. The path to codevelop a successful companion diagnostic with its complementary drug is complex, fragmented and fraught with several challenges. In this article, we discuss the logistic, strategic business, regulatory and financial challenges involved in drug-companion diagnostic codevelopment.Keywords
This publication has 25 references indexed in Scilit:
- HER2 testing in gastric cancer: a practical approachLaboratory Investigation, 2012
- HER-2/neu Overexpression is an Independent Prognostic Factor for Intestinal-type and Early-stage Gastric Cancer PatientsJournal of Clinical Gastroenterology, 2012
- Analytical Performance of a Real-time PCR-based Assay for V600 Mutations in the BRAF Gene, Used as the Companion Diagnostic Test for the Novel BRAF Inhibitor Vemurafenib in Metastatic MelanomaDiagnostic Molecular Pathology, 2012
- The cost-effectiveness of screening lung cancer patients for targeted drug sensitivity markersBritish Journal of Cancer, 2012
- Current management and novel agents for malignant melanomaJournal of Hematology & Oncology, 2012
- ALK Inhibition for Non-Small Cell Lung Cancer: From Discovery to Therapy in Record TimeCancer Cell, 2010
- Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung CancerNew England Journal of Medicine, 2010
- Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanomaNature, 2010
- Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast CancerNew England Journal of Medicine, 2005
- Mutations of the BRAF gene in human cancerNature, 2002